Protara Therapeutics, Inc. (TARA)

Market Cap	143.39M
Revenue (ttm)	n/a
Net Income (ttm)	-44.60M
Shares Out	36.77M
EPS (ttm)	-2.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	445,691
Open	4.000
Previous Close	4.000
Day's Range	3.930 - 4.025
52-Week Range	1.595 - 10.480
Beta	1.59
Analysts	Strong Buy
Price Target	20.00 (+412.82%)
Earnings Date	May 1, 2025

About TARA

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headqu...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Jesse Shefferman
• Employees: 33
• Stock Exchange: NASDAQ
• Ticker Symbol: TARA
• Website: https://www.protaratx.com

Analyst Forecast

According to 5 analysts, the average rating for TARA stock is "Strong Buy." The 12-month stock price forecast is $20.0, which is an increase of 412.82% from the latest price.

Price Target

$20.0

(412.82% upside)

Analyst Consensus: Strong Buy